Wall Street brokerages predict that Radius Health (NASDAQ:RDUS) will report sales of $20.27 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Radius Health’s earnings. The lowest sales estimate is $18.31 million and the highest is $21.50 million. Radius Health posted sales of $980,000.00 in the same quarter last year, which suggests a positive year-over-year growth rate of 1,968.4%. The business is scheduled to issue its next earnings results on Thursday, August 2nd.
On average, analysts expect that Radius Health will report full-year sales of $83.18 million for the current year, with estimates ranging from $33.00 million to $108.48 million. For the next fiscal year, analysts expect that the business will post sales of $159.62 million per share, with estimates ranging from $78.47 million to $226.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that follow Radius Health.
Radius Health (NASDAQ:RDUS) last released its earnings results on Thursday, May 10th. The biopharmaceutical company reported ($1.37) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.46) by $0.09. The firm had revenue of $14.50 million for the quarter, compared to the consensus estimate of $13.80 million. Radius Health had a negative return on equity of 108.95% and a negative net margin of 706.11%. During the same quarter in the previous year, the company posted ($1.32) EPS.
Several research firms have recently weighed in on RDUS. Morgan Stanley boosted their target price on Radius Health from $57.00 to $61.00 and gave the company an “overweight” rating in a research report on Friday, March 2nd. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $58.00 price objective on shares of Radius Health in a research report on Friday, May 11th. BidaskClub downgraded Radius Health from a “hold” rating to a “sell” rating in a research report on Wednesday, May 2nd. ValuEngine raised Radius Health from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Finally, Leerink Swann started coverage on Radius Health in a research report on Thursday, March 29th. They issued an “outperform” rating and a $53.00 price objective on the stock. Three investment analysts have rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company. Radius Health has a consensus rating of “Hold” and an average target price of $50.89.
In other news, major shareholder Growth N. V. Biotech purchased 50,000 shares of the company’s stock in a transaction dated Thursday, April 5th. The shares were acquired at an average price of $36.58 per share, with a total value of $1,829,000.00. Following the transaction, the insider now owns 5,903,799 shares of the company’s stock, valued at $215,960,967.42. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Growth N. V. Biotech purchased 40,000 shares of the company’s stock in a transaction dated Wednesday, May 23rd. The shares were purchased at an average cost of $28.91 per share, for a total transaction of $1,156,400.00. Following the transaction, the insider now directly owns 6,150,913 shares in the company, valued at approximately $177,822,894.83. The disclosure for this purchase can be found here. Insiders acquired a total of 270,000 shares of company stock worth $8,695,200 in the last ninety days. 3.42% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently bought and sold shares of RDUS. Consonance Capital Management LP bought a new position in shares of Radius Health during the 4th quarter worth $84,168,000. OppenheimerFunds Inc. bought a new position in shares of Radius Health during the 1st quarter worth $29,903,000. TimesSquare Capital Management LLC grew its position in shares of Radius Health by 16.2% during the 4th quarter. TimesSquare Capital Management LLC now owns 1,871,445 shares of the biopharmaceutical company’s stock worth $59,456,000 after buying an additional 261,080 shares in the last quarter. Eversept Partners LLC bought a new position in shares of Radius Health during the 4th quarter worth $6,179,000. Finally, BB Biotech AG grew its position in shares of Radius Health by 2.7% during the 1st quarter. BB Biotech AG now owns 5,853,799 shares of the biopharmaceutical company’s stock worth $210,386,000 after buying an additional 155,000 shares in the last quarter.
Shares of NASDAQ RDUS traded down $0.21 during trading hours on Monday, hitting $28.70. 599,703 shares of the company traded hands, compared to its average volume of 817,479. The company has a market cap of $1.32 billion, a P/E ratio of -4.95 and a beta of 1.27. The company has a debt-to-equity ratio of 0.87, a quick ratio of 6.41 and a current ratio of 6.55. Radius Health has a 12 month low of $24.66 and a 12 month high of $49.16.
About Radius Health
Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide that is in Phase III clinical trial to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator that is in Phase I clinical trial to treat breast cancer.
Get a free copy of the Zacks research report on Radius Health (RDUS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.